Related Experiment Video
Updated: Jul 13, 2026

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
Aortic valve replacement and coronary revascularization in paroxysmal nocturnal hemoglobinuria
Karsten Knobloch1, Artur Lichtenberg, Rainer G Leyh
1Department of Cardiothoracic and Vascular Surgery, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. knobloch@thg.mh-hannover.de
Abstract:
Cardiac surgery in patients with paroxysmal nocturnal hemoglobinuria (PNH), which is an acquired hemolytic anemia associated with thrombocytopenia and an abnormal susceptibility to venous thromboses, requires special perioperative measures. PNH is based on a clonal defect of hematopoietic stem cells characterized by deficiency in glycosyl-phosphatidylinositol-anchored surface proteins. The major mechanism of hemolysis consists of unregulated complement activation. In cardiac surgery, PNH-induced granulocytopenia increases the risk of postoperative infection. PNH-induced complement activation is further exaggerated by extracorporeal circulation in cardiac surgery leading to putative hemolytic crisis. Here, we report on a patient who developed PNH after severe aplastic anemia undergoing aortic valve replacement and coronary revascularization using extracorporeal circulation and discuss the special perioperative management and the relevant literature on this issue. Special emphasis should be given to optimal preoperative patient preparation including G-CSF administration and red blood pack transfusions, perioperative platelet substitution, fluid management, and antibiotic prophylaxis.
Related Concept Videos
Aortic Regurgitation III: Medical Management
Cardiomyopathy V: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Continuous Renal Replacement Therapy
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

